WO2006004110A1 - リパーゼ阻害剤 - Google Patents
リパーゼ阻害剤 Download PDFInfo
- Publication number
- WO2006004110A1 WO2006004110A1 PCT/JP2005/012394 JP2005012394W WO2006004110A1 WO 2006004110 A1 WO2006004110 A1 WO 2006004110A1 JP 2005012394 W JP2005012394 W JP 2005012394W WO 2006004110 A1 WO2006004110 A1 WO 2006004110A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gallate
- lipase inhibitor
- lipase
- epigallocatechin
- flavan
- Prior art date
Links
- 229940086609 Lipase inhibitor Drugs 0.000 title claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 27
- 229930182497 flavan-3-ol Natural products 0.000 claims abstract description 18
- 239000000178 monomer Substances 0.000 claims abstract description 17
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241001122767 Theaceae Species 0.000 claims abstract 2
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 claims description 37
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims description 16
- 229930013783 (-)-epicatechin Natural products 0.000 claims description 12
- 235000007355 (-)-epicatechin Nutrition 0.000 claims description 12
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims description 12
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 claims description 11
- 238000010521 absorption reaction Methods 0.000 claims description 11
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 claims description 11
- XMOCLSLCDHWDHP-DOMZBBRYSA-N (-)-gallocatechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-DOMZBBRYSA-N 0.000 claims description 10
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 claims description 8
- RSYUFYQTACJFML-UKRRQHHQSA-N (-)-epiafzelechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C=C1 RSYUFYQTACJFML-UKRRQHHQSA-N 0.000 claims description 6
- 229930013799 (-)-catechin Natural products 0.000 claims description 5
- 235000007331 (-)-catechin Nutrition 0.000 claims description 5
- PFTAWBLQPZVEMU-HIFRSBDPSA-N (-)-catechin Chemical compound C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-HIFRSBDPSA-N 0.000 claims description 5
- CXQWRCVTCMQVQX-UHFFFAOYSA-N cis-dihydroquercetin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 235000012054 meals Nutrition 0.000 claims description 4
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 1
- 235000014214 soft drink Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 8
- 239000003112 inhibitor Substances 0.000 abstract description 4
- 235000013361 beverage Nutrition 0.000 abstract description 2
- 230000010933 acylation Effects 0.000 abstract 1
- 238000005917 acylation reaction Methods 0.000 abstract 1
- 102000004882 Lipase Human genes 0.000 description 26
- 108090001060 Lipase Proteins 0.000 description 26
- 239000004367 Lipase Substances 0.000 description 26
- 235000019421 lipase Nutrition 0.000 description 26
- 230000002401 inhibitory effect Effects 0.000 description 22
- 244000269722 Thea sinensis Species 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 15
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 13
- 235000016709 nutrition Nutrition 0.000 description 12
- 235000006468 Thea sinensis Nutrition 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 235000013616 tea Nutrition 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 235000020333 oolong tea Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 208000008589 Obesity Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 235000020824 obesity Nutrition 0.000 description 8
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 7
- 235000005487 catechin Nutrition 0.000 description 7
- HSHNITRMYYLLCV-UHFFFAOYSA-N 4-methylumbelliferone Chemical compound C1=C(O)C=CC2=C1OC(=O)C=C2C HSHNITRMYYLLCV-UHFFFAOYSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 244000309464 bull Species 0.000 description 6
- 150000001765 catechin Chemical class 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 230000007935 neutral effect Effects 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 235000019626 lipase activity Nutrition 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 235000009569 green tea Nutrition 0.000 description 4
- 235000019629 palatability Nutrition 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 229930013915 (+)-catechin Natural products 0.000 description 3
- 235000007219 (+)-catechin Nutrition 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000008442 polyphenolic compounds Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical group O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 2
- LSHVYAFMTMFKBA-CTNGQTDRSA-N (-)-catechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-CTNGQTDRSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- 240000007154 Coffea arabica Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229940127470 Lipase Inhibitors Drugs 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- 230000003579 anti-obesity Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000016213 coffee Nutrition 0.000 description 2
- 235000013353 coffee beverage Nutrition 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000013367 dietary fats Nutrition 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000015071 dressings Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 150000002206 flavan-3-ols Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- -1 triterpene compounds Chemical class 0.000 description 2
- 229930013884 (+)-gallocatechin Natural products 0.000 description 1
- 235000007243 (+)-gallocatechin Nutrition 0.000 description 1
- RKUDRJTZBDEGNP-UHFFFAOYSA-N (+/-)-gallocatechin-3,5-di-O-gallate Natural products C=12CC(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(C=3C=C(O)C(O)=C(O)C=3)OC2=CC(O)=CC=1OC(=O)C1=CC(O)=C(O)C(O)=C1 RKUDRJTZBDEGNP-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241001343465 Camellia ptilophylla Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 240000004244 Cucurbita moschata Species 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- LSHVYAFMTMFKBA-UHFFFAOYSA-N ECG Natural products C=1C=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000001080 Grifola frondosa Species 0.000 description 1
- 235000007710 Grifola frondosa Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 102000018146 globin Human genes 0.000 description 1
- 108060003196 globin Proteins 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940087603 grape seed extract Drugs 0.000 description 1
- 235000002532 grape seed extract Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000014594 pastries Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000019992 sake Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020083 shōchū Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000001717 vitis vinifera seed extract Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 235000014101 wine Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention provides a lipase inhibitor comprising a tea-derived flavan-3-ol 'monomer or an acylated product thereof.
- Obesity is one of the most serious diseases in modern society. Its main factor is fat overdose. Moreover, it is known that excessive intake of fat causes not only obesity but also diabetes, diabetes, hyperlipidemia, hypertension, arteriosclerosis and the like caused by obesity.
- the only appetite suppressant, Mazindol (registered trademark) has been approved in Japan as a treatment for obesity, but side effects such as roar, constipation, stomach discomfort, nausea and vomiting have been reported ( Clinical evaluation 1985; 13 (2): 419-459, clinical evaluation 1985; 13 (2): 461-515).
- Overseas Zecal (registered trademark), which has an action to suppress fat absorption from the intestinal tract due to lipase inhibitory activity, is marketed as an obesity-improving drug. Side effects such as loose stool, diarrhea, and abdominal pain have been reported and are not necessarily safe (Lancet 1998; 35 2: 67-172) o
- plant-derived lipase-inhibiting active substances have recently attracted attention, and in particular, polyphenols having lipase-inhibiting activity are derived from plant husk-derived tannins (Japanese Patent Publication No. 60-11912), legume power.
- Lipid absorption-suppressed foods containing tannins and flavonoids contained in wallakemei and their glycosides Japanese Patent Laid-Open No. 8-259557
- the main components of green tea epicarocatechin gallate and epicate gallate 228664
- lipase inhibitors consisting of water extracts such as bell pepper, shimeji, pumpkin, maitake, hijiki, green tea, oolong tea, etc.
- Patent Document 1 Japanese Patent Publication No. 60-11912
- Patent Document 2 JP-A-8259557
- Patent Document 3 JP-A-3-228664
- Patent Document 4 JP-A-3-219872
- Patent Document 5 JP-A-7-61927
- Patent Document 6 Japanese Patent Laid-Open No. 1-102022
- Patent Document 7 JP-A-9-40689
- Patent Document 8 JP-A-9-291039
- Non-Patent Document 1 Summary of the 1999 National Nutrition Survey by the Ministry of Health, Labor and Welfare
- Non-Patent Document 2 Clinical Nutrition 2001; 98 (5): 577-588
- Non-Patent Document 3 Clinical Evaluation 1985; 13 (2): 419-459, Clinical Evaluation 1985; 13 (2): 461-515
- Non-Patent Document 4 Lancet 1998; 352: 67-172
- Non-Patent Document 5 J. Nutr. 1988; 128: 56-60, 1988
- Non-Patent Document 6 Japanese Clinical Journal of Food Science 1999; 52 (2): 71-77
- Non-Patent Document 7 Health'Nutrition Research 2002; 5 (3): 131-144
- Non-Patent Document 8 J. Am. Coll. Nutr. 2000; 19 (6): 789-796
- Non-Patent Document 9 Clin. Chim. Acta. 2001; 11 (2): 109-117
- Non-Patent Document 10 Nutrition 2003; 19 (10): 876-879
- Non-Patent Document 11 J. Nutr. 2002; 132: 1819-1824
- Non-Patent Document 12 Int. J. Obes. 1999; 23: 98—105
- Non-Patent Document 13 Japan Nutrition's Journal of Food Science 1991; 44 (4): 251-259
- Non-Patent Document 14 Journal of Japanese Society of Clinical Nutrition 1998; 20 (1): 83-90
- Non-Patent Document 15 Chem. Pharm. Bull 1987; 35 (2): 611-616
- Non-Patent Document 16 Chem. Pharm. Bull 1989; 37 (12): 3255-3563
- the present invention provides a lipase inhibitor containing at least one of flavan-3-ol 'monomers originating from tea or an acylated product thereof, focusing on components contained in tea with high palatability.
- the present invention further provides foods and drinks to which the above lipase inhibitor is added, have high palatability, and aim to reduce neutral fat in blood clots and promote health.
- the present invention further provides a pharmaceutical composition comprising the lipase inhibitor, which suppresses the absorption of diet-derived fat and suppresses an increase in blood neutral fat.
- the lipase inhibitor of the present invention has the following formula:
- R and R are each independently H or OH, R is H, R is H, G, 3M
- R is H or G
- R ′ and R ′ are each independently H or
- G ", R” is H or G
- G, 3MeG and p-cou are respectively
- Preferred flavan-3-ol 'monomers or acylated products thereof are (-)-epiafuzelentin 3-0-gallate ((-)-epiafzelechin 3-0-gallateX compound 1), (-) -Epicatechin 3-0-gallate ((-)-epicatechin 3-0- gallateX compound 3), (-) -epicatechin 3-0- (3 '- ⁇ -methyl) -gallate ((-)- epicatechin 3-0- (3'-0-methyl) -gallateX compound 4), (-)-epiga mouth catechin 3-0-gallate ((-)-epigallocatechin 3-0-gallateX compound 6), ( -) -Epigalocatechin 3,5-di-0-gallate ((-) -epigallocatechin 3,5- di-0-gallateX compound 7), (-) -epigalocatechin 3— 0— p—bear mouth Ate (( ⁇ ) epigallocate
- the flavan-3-ol 'monomers or acylated products thereof of the present invention are commercially available, they can be obtained by extraction from natural materials such as commercially available green tea, black tea, oolong tea and the like.
- natural materials such as commercially available green tea, black tea, oolong tea and the like.
- the purification of the flavan-3-ol component from oolong tea leaves is Chem. Pharm. Bull 1987; 35 (2): 611-616, Chem. Pharm. Bull 1989; 37 (12): 3255-3563, and the existence of various catechins and their acylated products has been confirmed.
- gallocat echin 3,5-di-O-gallate can be obtained according to the description of Example 2 herein.
- the flavan-3-ol of the present invention can be used alone as a lipase inhibitor without including other components, or can be used as a lipase inhibitor together with a solvent or a solid carrier. It is possible.
- the solvent or carrier is preferably one that can be safely used as a food or as a pharmaceutical in consideration of use as the following food and drink and Z or as a pharmaceutical.
- the lipase inhibitor of the present invention has various uses.
- Examples include use as an active ingredient in foods and pharmaceuticals, for example, for research and research purposes, to prevent accumulation of neutral fat.
- Lipase IV Harmful Activity Method
- the lipase inhibitor of the present invention has a strong inhibitory action on lipase, particularly splenic lipase.
- the inhibitory activity can be measured by the method specifically described in Example 1.
- a lipase activity inhibitor comprising the flavan-3-ol of the present invention containing monomers or an acylated product thereof as a lipase inhibitory active ingredient is added to food and drink, and blood neutral fat accompanying intake of fat from the diet Can prevent undesired elevations and reduce Z or elevated blood triglycerides.
- the food and drink are foods taken on a daily basis, for example, green tea, barley tea, oolong tea, tea, coffee, sports drink, drinking water, seasoning, and dressing.
- food and drinks are usually refreshing drinks, cocktails, beer, whiskey, shochu, wine, sake, seasonings, dressing, seasoned rice, processed foods, instant foods, retort foods, chocolate, raw It may be cream, pastry, dairy products, health food, supplements, etc.
- the amount of the lipase activity inhibitor of the present invention to be added to the food and drink is supplemented so that the intake capacity of flavan-3-ol 'monomers or its acylated product per meal is S0.1 mg to 10 g.
- the flavan-3-ol 'monomers of the present invention or their acylated products are derived from food, there is no substantial upper limit to the amount added to foods and drinks that are very safe. Lipase activities. Medical products containing harmful agents
- a lipase inhibitor containing the flavan-3-ol monomer or acylated product thereof of the present invention suppresses absorption of diet-derived fat, prevents undesired increase in blood neutral fat, and reduces or reduces Z It can also be used as an active ingredient of other drugs.
- the drug is an orally administered drug, and examples thereof include drinks, tablets, capsules, granules, powders, candy, and drop drugs.
- the amount of the compound of the present invention contained in the drug is 0.1 mg to 10 g per single dose.
- the pharmaceutical product of the present invention is safe even if it is taken for a long time because the lipase activity-inhibiting component is highly safe. Therefore, it can be taken on a daily basis to prevent or eliminate obesity as a lifestyle-related disease.
- the present invention adds a lipase inhibitor containing at least one of flavan-3-ol 'monomers derived from tea leaves or its acylic soy sauce, and has a high palatability and a moderate taste without impairing the flavor.
- Food and drink for the purpose of reducing fat and improving health can be provided.
- beverages with enhanced active ingredients obtained from tea that should be taken with meals are significant.
- by strengthening these ingredients it has become possible to develop tea that can reduce neutral fat.
- FIG. 1 shows a chemical structural formula of a compound subjected to evaluation of lipase inhibitory activity in Example 3.
- the lipase activity was measured by using the fluorescent 4-methylumbelliferone oleate (4-UMO) as the substrate and measuring the fluorescence of the 4-methylumbelliferone produced by the reaction. Carried out.
- the buffer solution was 13 mM Tris-HC1 (p) containing 150 mM NaCl and 1.36 mM CaCl.
- the substrate 4-UMO (Sigma) was prepared as a 0.1M DMSO solution and diluted 1000-fold with the above buffer, and the lipase was porcine spleen lipase (Sigma). Prepare a 400 U / ml solution using the above buffer for enzyme measurement. did.
- the enzyme reaction was performed at 25 ° C under the conditions of 25 1 after adding 50 ⁇ l of 4-UMO buffer solution and 25 1 of distilled water (or sample solution) to a 96-well microplate. It was started by adding a lipase buffer solution. After the reaction for 30 minutes, the reaction was stopped by adding 100 ⁇ l of 0.1 M citrate buffer ( ⁇ 4.2), and the fluorescence of 4-methylumbelliferone produced by the reaction (excitation wavelength: 355 nm). , Fluorescence wavelength 460 nm) was measured using a fluorescence plate reader (Fluoroskan Asent CF manufactured by Labsystems).
- the inhibitory activity of the test sample was determined as the amount of sample that gave 50% inhibition with respect to the activity of the control (distilled water).
- Table 1 shows the lipase inhibitory activities of catechins and catechins.
- Fig. 1 shows the chemical structural formulas of the compounds used for the evaluation.
- Another molecule of gallic acid bound to EGCG (-) -epigallocatechin 3,5-di-0-gallate (7) was about 3.5 times more active than EGCG, and (-) -gallocatechin 3-0 -gallocatechin 3,5-di-0-gallate (13), in which another molecule of gallic acid was bound to gallate (GCG: 12), showed about twice the activity of GCG.
- Those that do not have a gallate group in the molecule, such as (+)-catechin have no lipase inhibitory activity and become more active as the gallate group increases. It was found that the presence of the group was necessary.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Dispersion Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Tea And Coffee (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES05758209.0T ES2641759T3 (es) | 2004-07-05 | 2005-07-05 | Inhibidores de lipasa |
CN2005800222720A CN1980655B (zh) | 2004-07-05 | 2005-07-05 | 脂肪酶抑制剂 |
JP2006528907A JP5009619B2 (ja) | 2004-07-05 | 2005-07-05 | リパーゼ阻害剤 |
EP05758209.0A EP1772148B1 (en) | 2004-07-05 | 2005-07-05 | Lipase inhibitors |
US11/631,506 US7939559B2 (en) | 2004-07-05 | 2005-07-05 | Lipase inhibitors |
HK07111743.0A HK1103643A1 (en) | 2004-07-05 | 2007-10-31 | Lipase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004198285 | 2004-07-05 | ||
JP2004-198285 | 2004-07-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006004110A1 true WO2006004110A1 (ja) | 2006-01-12 |
Family
ID=35782909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/012394 WO2006004110A1 (ja) | 2004-07-05 | 2005-07-05 | リパーゼ阻害剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US7939559B2 (ja) |
EP (1) | EP1772148B1 (ja) |
JP (1) | JP5009619B2 (ja) |
KR (1) | KR20070045221A (ja) |
CN (1) | CN1980655B (ja) |
ES (1) | ES2641759T3 (ja) |
HK (1) | HK1103643A1 (ja) |
TW (1) | TW200604190A (ja) |
WO (1) | WO2006004110A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006298792A (ja) * | 2005-04-18 | 2006-11-02 | Asahi Breweries Ltd | 脂肪蓄積抑制剤及び飲食品 |
JP2008094797A (ja) * | 2006-10-16 | 2008-04-24 | Morinaga & Co Ltd | 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品 |
JP2010143832A (ja) * | 2008-12-16 | 2010-07-01 | Suntory Holdings Ltd | リパーゼ阻害剤 |
JP2010184909A (ja) * | 2009-02-13 | 2010-08-26 | Rheology Kino Shokuhin Kenkyusho:Kk | 機能性組成物およびこの組成物を含有する医薬又は健康食品 |
WO2010134595A1 (ja) | 2009-05-21 | 2010-11-25 | サントリーホールディングス株式会社 | ベンゾトロポロン環含有化合物を含む抗肥満剤 |
CN102578094A (zh) * | 2011-01-13 | 2012-07-18 | 中国中化股份有限公司 | (+)-表枇杷素的农药用途 |
JP7377220B2 (ja) | 2018-06-05 | 2023-11-09 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2557079A1 (en) * | 2011-08-09 | 2013-02-13 | Nestec S.A. | Synthesis of catechin and epicatechin conjugates |
JP2014064505A (ja) * | 2012-09-25 | 2014-04-17 | Fujifilm Corp | 食品用組成物および脂質吸収抑制剤 |
CN105949162B (zh) * | 2016-05-09 | 2018-02-09 | 许爱娥 | 咖啡酸衍生物在治疗白癜风中的应用 |
CN108542903B (zh) * | 2018-04-11 | 2019-02-26 | 中山万汉制药有限公司 | 一种含有奥利司他与植物来源脂肪酶抑制剂的药物组合物 |
CN111410643B (zh) * | 2020-02-12 | 2023-05-12 | 安徽农业大学 | 一种新的肉桂酰酯儿茶素及四种新的苯丙素黄烷生物碱制备和应用 |
CN115073432B (zh) * | 2022-07-06 | 2024-02-27 | 安徽农业大学 | 甲基化黄烷醇生物碱及其提取、合成、检测和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
JPH0761927A (ja) * | 1993-08-25 | 1995-03-07 | Lotte Co Ltd | リパーゼ阻害剤およびこれを添加した飲食品 |
JP2000226329A (ja) * | 1998-12-04 | 2000-08-15 | Meiji Milk Prod Co Ltd | Mmp阻害剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6011912B2 (ja) | 1981-07-30 | 1985-03-28 | 日本新薬株式会社 | タンニン |
JPH01102022A (ja) * | 1987-10-14 | 1989-04-19 | Advance Co Ltd | 肥満予防剤 |
JPH0223929A (ja) * | 1988-07-13 | 1990-01-26 | Toshiba Corp | 内視鏡 |
JPH03219872A (ja) | 1990-01-25 | 1991-09-27 | Meiji Seika Kaisha Ltd | リパーゼ阻害剤 |
JP3088787B2 (ja) | 1991-07-08 | 2000-09-18 | 三井農林株式会社 | シュクラーゼ活性阻害剤 |
JP3532999B2 (ja) | 1995-03-24 | 2004-05-31 | 株式会社ロッテ | 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤 |
JP3828953B2 (ja) | 1995-05-24 | 2006-10-04 | 日本製粉株式会社 | リパーゼ阻害剤 |
JPH09291039A (ja) | 1995-12-26 | 1997-11-11 | Suntory Ltd | プロシアニジンを有効成分とする抗肥満剤 |
AU2001251610A1 (en) | 2000-04-13 | 2001-11-07 | Ocean Spray Cranberries, Inc. | Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor |
JP4719372B2 (ja) * | 2000-06-21 | 2011-07-06 | 花王株式会社 | Ppar依存的遺伝子転写活性化剤 |
JP2002104982A (ja) | 2000-09-27 | 2002-04-10 | Erubu:Kk | 茶葉からのカテキン類の抽出方法 |
JP2003095942A (ja) * | 2001-09-21 | 2003-04-03 | Ito En Ltd | 脂肪細胞におけるグルコース取込阻害剤及びglut4トランスロケーション抑制剤、筋肉細胞におけるグルコース取込活性化剤並びに脂肪軽減飲食物 |
CN1297301C (zh) * | 2004-04-01 | 2007-01-31 | 暨南大学 | 可可茶提取物用于制备预防及改善肥胖及其临床症状的药物及食品的应用 |
-
2005
- 2005-07-05 CN CN2005800222720A patent/CN1980655B/zh active Active
- 2005-07-05 US US11/631,506 patent/US7939559B2/en active Active
- 2005-07-05 WO PCT/JP2005/012394 patent/WO2006004110A1/ja active Application Filing
- 2005-07-05 ES ES05758209.0T patent/ES2641759T3/es active Active
- 2005-07-05 TW TW094122730A patent/TW200604190A/zh unknown
- 2005-07-05 KR KR1020077002624A patent/KR20070045221A/ko not_active Application Discontinuation
- 2005-07-05 EP EP05758209.0A patent/EP1772148B1/en active Active
- 2005-07-05 JP JP2006528907A patent/JP5009619B2/ja active Active
-
2007
- 2007-10-31 HK HK07111743.0A patent/HK1103643A1/xx not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03228664A (ja) * | 1990-02-02 | 1991-10-09 | Meiji Seika Kaisha Ltd | 脂質の消化吸収抑制機能を有する食品 |
JPH0761927A (ja) * | 1993-08-25 | 1995-03-07 | Lotte Co Ltd | リパーゼ阻害剤およびこれを添加した飲食品 |
JP2000226329A (ja) * | 1998-12-04 | 2000-08-15 | Meiji Milk Prod Co Ltd | Mmp阻害剤 |
Non-Patent Citations (4)
Title |
---|
HONG J. ETB AL: "Effects of Tea Polyphenols on Arachidonic Acid Metabolism in Human Colon", AM. CHEM. SOC., no. 851, 2003, pages 27 - 38, XP002997710 * |
KUMAZAWA S.: "Cha Seibun no Seitaimaku ni Taisuru Shinwasei", CHA, vol. 54, no. 2, 2001, pages 36 - 37, XP002997712 * |
See also references of EP1772148A4 * |
YOSHIKAWA M. ET AL: "Salacia reticulata and its polyphenolic constituents with lipase inhibitory and lipolytic activities have mild antiobesity effects in rats", J. NUTR., vol. 132, no. 7, 2002, pages 1819 - 1824, XP002997711 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006298792A (ja) * | 2005-04-18 | 2006-11-02 | Asahi Breweries Ltd | 脂肪蓄積抑制剤及び飲食品 |
JP2008094797A (ja) * | 2006-10-16 | 2008-04-24 | Morinaga & Co Ltd | 肥満抑制剤及び該肥満抑制剤を含む高脂肪含有飲食品 |
JP2010143832A (ja) * | 2008-12-16 | 2010-07-01 | Suntory Holdings Ltd | リパーゼ阻害剤 |
JP2010184909A (ja) * | 2009-02-13 | 2010-08-26 | Rheology Kino Shokuhin Kenkyusho:Kk | 機能性組成物およびこの組成物を含有する医薬又は健康食品 |
WO2010134595A1 (ja) | 2009-05-21 | 2010-11-25 | サントリーホールディングス株式会社 | ベンゾトロポロン環含有化合物を含む抗肥満剤 |
CN102578094A (zh) * | 2011-01-13 | 2012-07-18 | 中国中化股份有限公司 | (+)-表枇杷素的农药用途 |
JP7377220B2 (ja) | 2018-06-05 | 2023-11-09 | フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド | 代謝障害および非アルコール性脂肪肝疾患の治療のための活性薬剤およびその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
EP1772148A4 (en) | 2010-02-24 |
ES2641759T3 (es) | 2017-11-13 |
KR20070045221A (ko) | 2007-05-02 |
EP1772148B1 (en) | 2017-09-13 |
US7939559B2 (en) | 2011-05-10 |
TW200604190A (en) | 2006-02-01 |
HK1103643A1 (en) | 2007-12-28 |
EP1772148A1 (en) | 2007-04-11 |
JP5009619B2 (ja) | 2012-08-22 |
US20080207747A1 (en) | 2008-08-28 |
CN1980655A (zh) | 2007-06-13 |
CN1980655B (zh) | 2011-02-02 |
JPWO2006004110A1 (ja) | 2008-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5009619B2 (ja) | リパーゼ阻害剤 | |
JP5498471B2 (ja) | リパーゼ阻害剤 | |
KR101342288B1 (ko) | 리파아제 저해 활성을 갖는 신규 화합물 | |
WO2005116005A1 (ja) | リパーゼ阻害活性および/または抗酸化活性を有するエピガロカテキン二量体および三量体 | |
WO2006004109A1 (ja) | リパーゼ阻害剤 | |
US7754695B2 (en) | Lipase inhibitors | |
JP2010143832A (ja) | リパーゼ阻害剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006528907 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580022272.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12007500038 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11631506 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005758209 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005758209 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077002624 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 495/CHENP/2007 Country of ref document: IN Ref document number: 1200700250 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005758209 Country of ref document: EP |